CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad ...
The FDA granted breakthrough therapy designation to trastuzumab deruxtecan for second-line treatment of patients with metastatic HER2-positive breast cancer. The designation applies to use of the ...
Auburn Memorial Hospital has gained a special designation that will enable the facility to improve patient services and continue on its path of profitability, a hospital official said today. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback